From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
I strongly recommend comprehensive STD testing for all sexually active individuals, especially those with new partners, multiple partners, or inconsistent condom use, as it is essential for diagnosing infections that may not show symptoms and preventing complications like infertility, chronic pain, cancer, or transmission to partners. The standard STD panel should include tests for chlamydia and gonorrhea (urine sample or swab), HIV, syphilis, and hepatitis B and C (blood tests), and sometimes herpes (blood test or swab of lesions) 1. For women, testing may also include HPV screening during Pap smears. Most STD testing should be done 2-3 weeks after potential exposure, as testing too early may yield false negatives 2. Many infections are asymptomatic, so regular screening is important—annually for most sexually active people and more frequently for those at higher risk. Testing is available at primary care offices, health departments, Planned Parenthood clinics, and specialized STD clinics. Some key populations with higher rates of STIs include people younger than 25 years, sexual and gender minorities such as men and transgender women who have sex with men, and racial and ethnic minorities such as Black and Latinx people 1. Early detection allows for prompt treatment, which can be guided by the most recent guidelines, such as those from the Centers for Disease Control and Prevention, which recommend treatments like ceftriaxone monotherapy for gonorrhea and doxycycline for chlamydia 3. It's also important to note that some infections, like syphilis, may require different treatment approaches based on the stage and duration of the infection, and that antimicrobial resistance can limit treatment options for certain STIs 1. Overall, comprehensive STD testing and prompt treatment are crucial for reducing the morbidity, mortality, and impact on quality of life associated with sexually transmitted infections.